Search

The Kaiser Family Foundation today released two new Spanish-language tools to help consumers better understand health insurance as they shop for plans during open enrollment for the Affordable Care Act’s marketplaces and in other venues. El seguro de salud, explicado: ¡los YouToons lo tienen cubierto!, is a Spanish version of…

With the approval of new specialty drugs, such as the Hepatitis C treatments Sovaldi and Harvoni, states are mindful that the cost the Medicaid prescription drug benefit could increase. To achieve savings, and improve management and health outcomes, it is important to understand which drugs are most frequently prescribed and which drive spending. Using state drug utilization data provided through the Medicaid Drug Rebate Program, as well as an industry drug database, this issue brief examines trends in prescriptions and spending before rebates, and places findings in the context of policy discussion.

This issue brief analyzes the number and variety of Medicare Advantage plan choices available to beneficiaries in 2015. It describes trends in number of Medicare Advantage plans, plan premiums, and plan quality ratings, including changes in prescription drug coverage and limits on out-of-pocket expenses. This spotlight is part of a series of spotlights tracking key changes in the Medicare Advantage program.

In this column for The Wall Street Journal’s Think Tank, Drew Altman examines the disconnect between Washington insiders and the public when it comes to attention paid to news stories like “Grubergate”.

This fact sheet provides an overview of the Center for Medicare and Medicaid Innovation (Innovation Center)’s State Innovation Models (SIM) initiative. It focuses on the delivery system and payment approaches that Model Testing states are taking and discusses what SIM means for Medicaid. Six states – Arkansas, Maine, Massachusetts, Minnesota, Oregon, and Vermont — received Model Testing awards to implement and test their Innovation Plans over 42 months.

A new Kaiser Family Foundation report finds that funding for global malaria control and elimination activities has risen from US$871 million in 2005 to US$2.6 billion in 2013. However, total funding is significantly below US$5.1 billion, the goal set by the Global Malaria Action Plan, which is a framework endorsed by…

This report finds that funding for global malaria control and elimination activities has risen from US$871 million in 2005 to US$2.6 billion in 2013. However, total funding is significantly below US$5.1 billion, the goal set by the Global Malaria Action Plan, which is a framework endorsed by world leaders in 2008 to reach global malaria reduction targets.
Additionally, support for malaria research and development (R&D) activities in 2013 was estimated to be US$549 million, below the estimated annual need of US$750-900 million and the lowest level of funding since 2007, the first year of available data.

In his latest column for The Wall Street Journal’s Think Tank, Drew Altman discusses this week’s Centers for Medicare and Medicaid Services report on health spending and assesses the current effort to control health-care costs.

The Kaiser Family Foundation, in partnership with the Peterson Center on Healthcare, today announced a new online hub dedicated to monitoring and assessing the performance of the U.S. health system. The Peterson-Kaiser Health System Tracker provides comprehensive data on how the system is performing on critical quality and cost measures,…